International Clinical Trial: Prospective, Non-randomized, Open-label Safety Study of Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Diabetic Foot Ulcers

Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121779) titled 'Prospective, Non-randomized, Open-label Safety Study of Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Diabetic Foot Ulcers' on April 2.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The Second Affiliated Hospital of Zhejiang University School of Medicine

Condition: Diabetic peripheral vascular disease and sugar foot ulcer

Intervention: DC-1 Low Dose Group:Mesenchymal stem cell exosomes (MSC-Exos), 5x10^10 particles per dose, local administration, weekly or as needed (based on wound healing status) DC-2 Medium Dose Group:Mesenchymal stem cell exosomes (MSC-Exos), 1...